Inventiva (NASDAQ:IVA) Sees Strong Trading Volume – Time to Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares saw strong trading volume on Thursday . 1,355,095 shares traded hands during trading, an increase of 192% from the previous session’s volume of 464,733 shares.The stock last traded at $3.5360 and had previously closed at $3.53.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IVA shares. Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Truist Financial initiated coverage on shares of Inventiva in a report on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $16.56.

Inventiva Trading Up 0.7%

The company has a 50 day moving average price of $4.95 and a 200 day moving average price of $5.38.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter. As a group, research analysts forecast that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Inventiva

Institutional investors have recently added to or reduced their stakes in the business. Creative Planning purchased a new position in Inventiva in the second quarter worth $32,000. Virtu Financial LLC purchased a new stake in shares of Inventiva during the 4th quarter worth $60,000. XTX Topco Ltd purchased a new stake in shares of Inventiva during the 4th quarter worth $84,000. NewEdge Advisors LLC acquired a new position in shares of Inventiva during the 3rd quarter worth $116,000. Finally, Cerity Partners LLC purchased a new position in shares of Inventiva in the 4th quarter valued at about $93,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.